Table 2.
Comparison of Practice Performance Rates During the Second Pre-EHR Period (p2) and Each Post-EHR Period
| Measure | Mean Performance Rate (Standard Deviation) in p2 for Practices with 10 or More Eligible Patients in All Measurement Periods | Number of Practices with 10 or More Eligible Patients in All Measurement Periods (N=35) | Number (percent) of Practices Meeting or Exceeding p2 Performance in e1* | Number (percent) of Practices Meeting or Exceeding p2 Performance in e2* | |
|---|---|---|---|---|---|
| Antithrombotic therapy | 25.6 | (17.3) | 24 | 23 (96%) | 23 (96%) |
| Blood pressure control | 48.3 | (15.4) | 27 | 23 (85%) | 27 (100%) |
| Body mass index recorded | 65.0 | (42.0) | 31 | 18 (58%) | 23 (74%) |
| Cholesterol testing | 78.9 | (20.5) | 30 | 10 (33%) | 16 (53%) |
| Cholesterol control | 80.3 | (8.6) | 26 | 24 (92%) | 26 (100%) |
| HbA1c testing | 67.4 | (17.7) | 23 | 14 (61%) | 20 (87%) |
| HbA1c control | 45.2 | (15.0) | 4 | 4 (100%) | 4 (100%) |
| Smoking status recorded | 62.3 | (34.5) | 31 | 23 (74%) | 25 (81%) |
| Smoking cessation intervention | 20.4 | (19.8) | 10 | 7 (70%) | 7 (70%) |
Notes:
*
On average, the end of e1 was 11 months after EHR go-live, and the end of e2 was 17 months after EHR go-live.
BP: Blood pressure; DM: Diabetes Mellitus; GP: General population; HbA1c: Hemoglobin A1c; HLP: Hyperlipidemia; HTN: Hypertension; IVD: Ischemic vascular disease; LDL: Low density lipoprotein